Filip Bednar

University of Michigan
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Supplementary Figure 3 shows gating strategies used for flow analysis of CD4 cells from orthotopic tumors as well as serum and tissue IL22 measured by ELISA. IHC and multiplex IHC analysis of TCDD treated tumors in the absence of T regulatory cells is shown.

Year:

2026

Although smoking is a risk factor for pancreatic adenocarcinoma (PDAC), the underlying mechanisms promoting tumorigenesis and progression are unknown. In this study, we show that aryl hydrocarbon receptor (AHR) ligands found in cigarette smoke, like the carcinogen 2,3,7,8-tetrachlorodibenzo- p -dioxin, promote pancreatic dysplasia and PDAC progression in a mouse model of this disease. This effect is mediated by AHR activation in CD4 + T cells, leading to their polarization to IL22 -producing TH22 cells and regulatory T cell accumulation, ultimately driving a blunted CD8 + T-cell effector response. Analysis of human pancreata from organ donors revealed that smokers have increased AHR activation relative to nonsmokers. Similarly, PDAC tumors from patients with a history of cigarette smoking presented with increased regulatory T-cell accumulation compared with nonsmokers. These findings support a model whereby AHR ligands (AHRL) in cigarette smoke promote tumorigenesis and progression of PDAC through dysregulation of immune responses. Significance: Our study investigates the mechanistic link between AHRL and pancreatic cancer. We determined that AHRLs polarize naïve T cells, resulting in increased production of IL22 and immunosuppression. Our findings identify a novel signaling axis linking environmental chemicals to pancreatic tumorigenesis via the immune system. See related commentary by Zhao and Hill, p. 13

Year:

2026

Supplementary Figure 1 provides additional details of orthotopic tumors treated with TCDD including histology, gross pictures and dose escalation. Data on additional cell lines including in vitro growth kinetics is provided.

Year:

2026

Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the United States. This is due in part to the limited availability of effective treatment options for patients, highlighting a significant need for new targets and approaches. Deregulated metabolism is a hallmark feature of PDA that has gained attention as a promising inroad for therapy. The aspartate transaminases ( g lutamate o xaloacetate transaminases, cytosolic GOT1 and mitochondrial GOT2) have several important metabolic functions, including maintaining energy and redox balance and generating aspartate, an essential building block in protein and nucleotide biosynthesis. Previous studies of GOT proteins in preclinical tumor transplant models have yielded conflicting results regarding the requirement of GOT1 and GOT2 for PDA tumor growth. To assess the role of GOT proteins in tumor development and tumor maintenance, we generated conditional knockout mice for Got1 and Got2 and crossed these into pancreas-specific models. Whereas loss of either Got does not impact pancreas development, double Got1 and Got2 knockout results in markedly reduced pancreas size and cellularity without overtly impacting endocrine or exocrine function. In genetically engineered cancer models, single Got loss does not impact lesion formation, tumor size, animal survival, or the composition of the tumor microenvironment. Identical results were also observed in orthotopic allograft mouse models. Together, these findings add to a growing body of work illustrating the adaptability of metabolism in cancer. They also emphasize the importance of model selection, the use of multiple independent models, and the in vivo context when studying the role of metabolic programs in cancer.

Year:

2025

Supplemental Table 1: Demographics and clinical data for donor Gife of Life Samples Supplemental Table 2: Putative Ligand-Receptor pairs comparing all cell types from single cell sequencing of tumor samples compared to healthy samples. Supplemental Table 3: Differential gene expression using linear mixed model analysis of cell types from spatial transcriptomic ROIs. Supplemental Table 4: Kras mutational profiling on select donor samples Supplemental Table 5: Antibodies used for multiplex immunofluoresence. Supplemental Table 6: Antibodies and RNAScope probe used for co-IF/ISH.

Year:

2025

Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). How chemotherapy alters the TME, and whether these changes drive chemoresistance, is poorly understood. We examined matched pre- and post-treatment tissue specimens and found near-universal enrichment of axonal guidance genes in cancer-associated fibroblasts (CAFs) after treatment. These CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrence lesions had the highest prevalence of these CAFs versus primary tumors and untreated metastasis. These CAFs showed elevated non-canonical Wnt mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Our findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising target for this disease. Statement of Significance Therapeutic resistance remains a major challenge in pancreatic cancer. Our findings shed light on the changes in the complex tumor microenvironment in response to chemotherapy and identify fibroblasts high in axonal-guidance genes that may drive tumor progression and chemoresistance, thus uncovering a potential avenue for targeting pancreatic cancer.

Year:

2025

Background & Aims Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that represent one of the few radiologically identifiable precursors to pancreatic ductal adenocarcinoma (PDAC). Though the IPMN-bearing patient population represents a unique opportunity for early detection and interception, current guidelines provide insufficient accuracy in determining which patients should undergo resection versus surveillance, resulting in a sizable fraction of resected IPMNs only harboring low-grade dysplasia, suggesting that there may be overtreatment of this clinical entity. Methods To investigate the transcriptional changes that occur during IPMN progression, we performed spatial transcriptomics using the Nanostring GeoMx on patient samples containing the entire spectrum of IPMN disease including low-grade dysplasia, high-grade dysplasia, and IPMN-derived carcinoma. Single cell RNA sequencing was performed on side branch and main duct IPMN biospecimens. Results We identified a subpopulation of histologically low-grade IPMN epithelial cells that express malignant transcriptional features including KRT17 , S100A10 and CEACAM5 , markers that are enriched in PDAC. We validated this high-risk gene signature in both single-cell RNA sequenced samples and an external ST dataset containing a larger number of IPMN samples including non-tumor bearing IPMN (i.e. low-grade IPMN in isolation). Immunofluorescence staining of a large cohort of patient tissues confirmed the presence of KRT17-positive cells, which were found to comprise a small subset of epithelial cells within histologically low-grade IPMN in a patchy distribution. Conclusions Our study demonstrates that KRT17 marks a distinct transcriptional signature in a subpopulation of epithelial cells within histologically low-grade IPMN. This population of cells likely represents a transitional state of histologically low-grade epithelial cells undergoing progression to a higher grade of dysplasia and thus may represent a higher risk of progression to carcinoma. Abstract Figure Graphical Abstract

Year:

2025

The adult healthy human pancreas has been poorly studied given the lack of indication to obtain tissue from the pancreas in the absence of disease and rapid postmortem degradation. We obtained pancreata from brain dead donors, thus avoiding any warm ischemia time. The 30 donors were diverse in age and race and had no known pancreas disease. Histopathologic analysis of the samples revealed pancreatic intraepithelial neoplasia (PanIN) lesions in most individuals irrespective of age. Using a combination of multiplex IHC, single-cell RNA sequencing, and spatial transcriptomics, we provide the first-ever characterization of the unique microenvironment of the adult human pancreas and of sporadic PanIN lesions. We compared healthy pancreata to pancreatic cancer and peritumoral tissue and observed distinct transcriptomic signatures in fibroblasts and, to a lesser extent, macrophages. PanIN epithelial cells from healthy pancreata were remarkably transcriptionally similar to cancer cells, suggesting that neoplastic pathways are initiated early in tumorigenesis. Significance: Precursor lesions to pancreatic cancer are poorly characterized. We analyzed donor pancreata and discovered that precursor lesions are detected at a much higher rate than the incidence of pancreatic cancer, setting the stage for efforts to elucidate the microenvironmental and cell-intrinsic factors that restrain or, conversely, promote malignant progression. See related commentary by Hoffman and Dougan, p. 1288. This article is highlighted in the In This Issue feature, p. 1275

Year:

2025

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor, predominantly triggered by the acquisition of mutant KRAS, and is present in approximately 95% of PDAC cases. The recent introduction of KRAS inhibitors has been a source of tremendous enthusiasm; however, therapeutic resistance has emerged, and combination approaches are needed. In particular, it is important to understand how downstream signaling of KRAS supports PDAC growth. For example, DUSP6, a dual-specificity phosphatase that modulates ERK1/2 phosphorylation and RAS pathway activity, has emerged as an important regulator of KRAS-MAPK signaling. Analysis across diverse bulk RNA-seq datasets revealed that DUSP6 is markedly overexpressed in primary tumor samples compared to non-tumoral pancreatic tissue. Interestingly, both human bulk and single-cell RNA-seq data indicated that DUSP6 was upregulated in epithelial cells within the tumor. Further examination showed that DUSP6 was also overexpressed in metastatic samples relative to primary tumor samples, and this upregulation correlated with the quasi-mesenchymal/squamous molecular subtype. Pertaining to its clinical significance, patients with high DUSP6 expression exhibited a poorer prognosis for overall survival than those with low expression. Subsequent gene set enrichment analysis of publicly available datasets revealed the enrichment of pathways associated with cell migration and metabolism in metastatic samples. To elucidate the role of DUSP6 in these pathways, we developed PDAC cell lines stably knocked down DUSP6 and observed a concurrent increase in ERK/MAPK activation. Additionally, suppression of DUSP6 demonstrated PDAC cell-specific alterations in migratory capacity . Next, we assessed the metabolism of PDAC cell lines following DUSP6 knockdown and observed a notable increase in basal glycolysis. Interestingly, despite the observed alterations in migratory capacity and glycolytic metabolism upon DUSP6 modulation, the combined approach of DUSP6 downregulation and glycolysis inhibition failed to affect the observed migratory phenotype, suggesting that glycolytic demands did not drive the migratory phenotype . In summary, these findings suggest that DUSP6 elicits two independent functions in PDAC: migratory capacity and glycolysis metabolism, providing new insights into the function of DUSP6 in PDAC.

Year:

2024

Cellular plasticity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) starting from the conversion of normal cells into precancerous lesions, to the progression of carcinoma subtypes associated with aggressiveness and therapeutic response. We discovered that normal acinar cell differentiation, maintained by the transcription factor PDX1, suppresses a broad gastric cell identity that is maintained in metaplasia, neoplasia, and the classical subtype of PDAC in a mouse and human. We identified the receptor tyrosine kinase ROR2 as marker of a gastric metaplasia-like identity in pancreas neoplasms. Ablation of Ror2 in a mouse model of pancreatic tumorigenesis promoted a switch to a gastric pit cell identity that largely persisted through progression to the classical subtype of PDAC. In both human and mouse pancreatic cancer, ROR2 activity continued to antagonize the gastric pit cell identity, strongly promoting an epithelial to mesenchymal transition, conferring resistance to KRAS inhibition, and vulnerability to AKT inhibition. Significance: We discovered the receptor tyrosine kinase ROR2 as an important regulator of cellular identity in pancreatic precancerous lesions and pancreatic cancer. ROR2 drives an aggressive PDAC phenotype and confers resistance to KRAS inhibitors, suggesting that targeting ROR2 will enhance sensitivity to this new generation of targeted therapies. See related commentary by Marasco and Misale, p. 2018

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (20)

Jonathan Preall

Research Associate Professor

Cold Spring Harbor Laboratory

UNITED STATES
View details

Christopher Sonnenday

University of Michigan

UNITED STATES
View details

Howard Crawford

Professor

University of Michigan

UNITED STATES
View details

Allison R. Schulman

University of Michigan

UNITED STATES
View details

Pierre A. Coulombe

G. Carl Huber Professor and Chair

University of Michigan

UNITED STATES
View details

Jorge Machicado

Assistant Professor

University of Michigan

UNITED STATES
View details

Marina Pasca Di Magliano

Associate Professor

University of Michigan

UNITED STATES
View details

Michael VanSaun

Associate Professor

University of Kansas Medical Center

UNITED STATES
View details

Ling Huang

Assistant Professor

Michigan State University

UNITED STATES
View details

Vaibhav Sahai

University of Michigan

UNITED STATES
View details

Benjamin Allen

Associate Professor

University of Michigan

UNITED STATES
View details

Jiaqi Shi

Professor

University of Michigan

UNITED STATES
View details

Ilona Kryczek

University of Michigan

UNITED STATES
View details

weiping Zou

University of Michigan

UNITED STATES
View details

Timothy Frankel

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Yaqing Zhang

Associate Professor

University of Michigan

UNITED STATES
View details

Rosa Menjivar

University of California, San Francisco

UNITED STATES
View details

William Burns

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

Nina Steele

Assistant Professor

University of Cincinnati

UNITED STATES
View details